Abstract
Summary: Isolated distal deep vein thrombosis (DVT) represents up to 50% of all lower limb DVT in ultrasound series and is a frequent medical condition, which management is not well established. Data arising from registries and non-randomized studies suggest that most distal DVTs do not extend to the proximal veins and have an uneventful follow-up when left untreated. This data had some impact on international recommendations like the American College of Chest Physicians (ACCP), whose last version stated that ultrasound surveillance might be an option for selected low-risk patients. However, robust data arising from randomized studies are scarce. Indeed, only seven randomized trials assessing the need for anticoagulation for calf DVT have been published. Many of these trials had an open-label design and were affected by methodological limitations. When considering randomized placebo-controlled trials, one included low-risk patients and was hampered by a limited statistical power (CACTUS study). Nevertheless, data from this trial tend to confirm that the use of therapeutic anticoagulation in low-risk patients with symptomatic calf DVT is not superior to placebo in reducing VTE but is associated with a higher risk of bleeding. A second randomized placebo-controlled trial did not assess the necessity of anticoagulant treatment but rather the long-term risk of recurrence and compared 6 weeks versus 12 weeks of treatment with rivaroxaban (RIDTS study). Finally, the last available randomized trial compared a 3-month versus a 12-month edoxaban treatment in patients with cancer and mainly asymptomatic distal DVT, detected by systematic compression ultrasonography. Overall, available data suggest that the use of therapeutic anticoagulation in low-risk patients with symptomatic calf DVT is not superior to placebo in reducing VTE. High risk patients (previous VTE, active cancer, inpatients) might benefit from a course of anticoagulant treatment. However, the optimal anticoagulant intensity and duration are uncertain and further studies are needed.
References
1 . Is it worth diagnosing and treating distal deep vein thrombosis? No. J Thromb Haemost. 2007;5(Suppl 1):55–9.
2 . Clinical relevance of distal deep vein thrombosis. Review of literature data. Thromb Haemost. 2006;95(1):56–64.
3 Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: results from the OPTIMEV study. Thromb Haemost. 2009;102(3):493–500.
4 Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S–94S.
5 . How I treat isolated distal deep vein thrombosis (IDDVT). Blood. 2014;123(12):1802–9.
6 . Distal DVT: worth diagnosing? Yes. J Thromb Haemost. 2007;5(Suppl 1):51–4.
7 . Practice variation in the management of distal deep vein thrombosis in primary vs. secondary cares: A clinical practice survey. Thromb Res. 2015;136(3):526–30.
8 . The controversy of managing calf vein thrombosis. J Vasc Surg. 2012;55(2):550–61.
9 Risk of deep vein thrombosis following a single negative whole-leg compression ultrasound: a systematic review and meta-analysis. Jama. 2010;303(5):438–45.
10 A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. J Intern Med. 1998;243(1):15–23.
11 Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial. JAMA. 2008;300(14):1653–9.
12 Safety and sensitivity of two ultrasound strategies in patients with clinically suspected deep venous thrombosis: a prospective management study. J Thromb Haemost. 2009;7(12):2035–41.
13 Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis. J Thromb Haemost. 2014;12(4):436–43.
14 Anticoagulant therapy for symptomatic distal deep vein thrombosis: the cactus randomized placebocontrolled trial. J Thromb Haemost. 2015;13(S2):50.
15 . Does this patient have deep vein thrombosis? Jama. 1998;279(14):1094–9.
16 Accuracy of clinical assessment of deep-vein thrombosis. Lancet. 1995;345(8961):1326–30.
17 . Distribution of thrombosis in patients with symptomatic deep vein thrombosis. Implications for simplifying the diagnostic process with compression ultrasound. Arch Intern Med. 1993;153(24):2777–80.
18 Diagnostic accuracy of compression ultrasonography for the detection of asymptomatic deep venous thrombosis in medical patients – the TADEUS project. Thromb Haemost. 2001;86(2):529–33.
19 . Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83(5):657–60.
20 . Deep venous thrombosis and the risk of pulmonary embolism. A systematic study. Chest. 1992;102(3):677–81.
21 . Systematic review of the complications following isolated calf deep vein thrombosis. Br J Surg. 2016;103(7):789–96.
22 D-dimer testing as an adjunct to ultrasonography in patients with clinically suspected deep vein thrombosis: prospective cohort study. The Multicentre Italian D-dimer Ultrasound Study Investigators Group. BMJ. 1998;317(7165):1037–40.
23 The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med. 1998;128(1):1–7.
24 Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ. 1998;316(7124):17–20.
25 Simplification of the diagnostic management of suspected deep vein thrombosis. Arch Intern Med. 2002;162(8):907–11.
26 Non-invasive diagnosis of venous thromboembolism in outpatients. Lancet. 1999;353(9148):190–5.
27 Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet. 1997;350(9094):1795–8.
28 Comparison of the clinical history of symptomatic isolated distal deep-vein thrombosis vs. proximal deep vein thrombosis in 11086 patients. J Thromb Haemost. 2009;7(12):2028–34.
29 Recurrence risk after first symptomatic distal versus proximal deep vein thrombosis according to baseline risk factors. TH Open. 2019;3(1):e58–e63.
30 Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism. J Thromb Haemost. 2017;15(7):1436–42.
31 . Two years outcome of isolated distal deep vein thrombosis. Thromb Res. 2014;134(1):36–40.
32 Comparison of the clinical history of symptomatic isolated muscular calf vein thrombosis versus deep calf vein thrombosis. J Vasc Surg. 2010;52(4):932–8. 938.e1–2.
33 Isolated distal deep vein thrombosis: what have we learnt from the OPTIMEV study? J Med Vasc. 2023;48(1):3–10.
34 . Calf deep vein thrombosis: Really a wolf in sheep’s clothing? J Med Vasc. 2023;48(1):1–2.
35 . The anticoagulation of calf thrombosis (ACT) project: results from the randomized controlled external pilot trial. Chest. 2014;146(6):1468–77.
36 . Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet. 1985;2(8454):515–8.
37 Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. 2001;103(20):2453–60.
38 . Therapy of isolated calf muscle vein thrombosis: a randomized, controlled study. J Vasc Surg. 2010;52(5):1246–50.
39 Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial. BMJ. 2022;379:e072623.
40 Edoxaban for 12 months versus 3 months in patients with cancer with isolated distal deep vein thrombosis (ONCO DVT Study): an open-label, multicenter, randomized clinical trial. Circulation. 2023;148(21):1665–76.
41 Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008;133(6 Suppl):454S–545S.
42 Therapeutic anticoagulation for isolated calf deep vein thrombosis. JAMA Surg. 2016;e161770.
43 Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study. Thromb Haemost. 2010;104(5):1063–70.
44 Isolated distal deep vein thrombosis: efficacy and safety of a protocol of treatment. Treatment of Isolated Calf Thrombosis (TICT) Study. Int Angiol. 2009;28(1):68–72.
45 Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315–52.
46 Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. Lancet Haematol. 2016;3(12):e556–e62.
47 Effect of anticoagulant treatment on pain in distal deep vein thrombosis: an ancillary analysis from the cactus trial. J Thromb Haemost. 2019;17(3):507–10.
48 Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. Eur J Prev Cardiol. 2022;29(8):1248–63.
49 Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med. 2010;363(13):1222–32.
50 . Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4.